Aquestive Therapeutics (AQST) Accumulated Depreciation & Amortization (2017 - 2025)
Historic Accumulated Depreciation & Amortization for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $43.9 million.
- Aquestive Therapeutics' Accumulated Depreciation & Amortization rose 124.78% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year increase of 124.78%. This contributed to the annual value of $43.5 million for FY2024, which is 143.88% up from last year.
- Latest data reveals that Aquestive Therapeutics reported Accumulated Depreciation & Amortization of $43.9 million as of Q3 2025, which was up 124.78% from $43.8 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $43.9 million for Q3 2025, and its period low was $37.8 million during Q1 2021.
- In the last 5 years, Aquestive Therapeutics' Accumulated Depreciation & Amortization had a median value of $42.5 million in 2023 and averaged $41.9 million.
- In the last 5 years, Aquestive Therapeutics' Accumulated Depreciation & Amortization crashed by 249.03% in 2021 and then skyrocketed by 711.3% in 2022.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Accumulated Depreciation & Amortization stood at $39.9 million in 2021, then grew by 5.28% to $42.0 million in 2022, then increased by 2.19% to $42.9 million in 2023, then increased by 1.44% to $43.5 million in 2024, then grew by 0.91% to $43.9 million in 2025.
- Its Accumulated Depreciation & Amortization was $43.9 million in Q3 2025, compared to $43.8 million in Q2 2025 and $43.6 million in Q1 2025.